Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Tatiana Schlossberg, JFK's granddaughter, dies at 35 after terminal cancer diagnosis - 2EU Council president: Ukraine should receive binding guarantees
- 3This cafe takes orders in sign language. It's cherished by the Deaf community
- 4Pick Your #1 Japanese Food
- 5The Fate of Mechanical technology: 5 Headways Forming Tomorrow
- Instructions to Pick the Right Toothbrush for Your Teeth
- Herzog, German Chancellor Merz discuss final Gaza hostage, Arrow 3 exchange in Jerusalem
- A Manual for Extravagant Vehicles Available in 2024
- Misremembering might actually be a sign your memory is working optimally
- November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up
- Really focusing on Succulents: Tips and Procedures
- Robert Pattinson claims he's a pathological liar. What 'The Drama' star has said about his 'shtick'
- 25 of the world’s best sandwiches
- The Force of Mentorship: Self-improvement through Direction
